-
Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model.
Wright D, Syngelaki A, Staboulidou I, Cruz JJ, Nicolaides KH.
Prenat Diagn 2011;31:16-21. -
First-trimester markers of aneuploidy in women positive for HIV.
Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
BJOG 2011;118:844-8. -
First-trimester prediction of macrosomia.
Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;29:139-47. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
Prenat Diagn 2011;31:38-45. -
Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness.
Vandecruys H, Faiola S, Auer M, Sebire N, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:551-3. -
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
Increased nuchal translucency with normal karyotype.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1005-21. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7.